General Information of Drug (ID: DMB9F2L)

Drug Name
PMID19115845C89S Drug Info
Synonyms 3du8; GTPL8114; BDBM27380; DB07149
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
16757525
TTD Drug ID
DMB9F2L

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flavopiridol DMKSUOI Acute myeloid leukaemia 2A60 Phase 2 [2]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [3]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
BTX-A51 DMC8XHQ Advanced solid tumour 2A00-2F9Z Phase 1 [6]
CYC065 DM9ODT6 Lymphoma 2A80-2A86 Phase 1 [2]
AZD4573 DMOYPTK Haematological malignancy 2B33.Y Phase 1 [2]
TP-1287 DM3Z07E Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
VIP-152 DMBQ5OL Chronic lymphocytic leukaemia 2A82.0 Phase 1 [8]
AZD7503 DM8XJD2 Non-alcoholic steatohepatitis DB92.1 Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [3]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [11]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [13]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [14]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [15]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [3]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
PHA848125 DMS2Q9G Thymic cancer 2C27 Phase 2 [16]
TG02 DMZFIGQ Anaplastic astrocytoma 2A00.0 Phase 1/2 [17]
NUV-422 DMQJQNT Malignant glioma 2A00.0 Phase 1/2 [18]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [4]
FN-1501 DM7BMD6 Solid tumour/cancer 2A00-2F9Z Phase 1 [19]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
SNS-032 DMEITAS Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [20]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [21]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [22]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [23]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [24]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [25]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [26]
CHIR-99021 DMB8MNU Allergic inflammation 4A80-4A85 Patented [27]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [28]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting CDC7-related kinase (CDC7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-863233 DM5HUY8 Haematological malignancy 2B33.Y Phase 1/2 [30]
TAK-931 DM1ALY9 Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PMID26161698-Compound-44 DM8UPO3 N. A. N. A. Patented [13]
PMID20873740C18 DMVHR3Z Discovery agent N.A. Investigative [31]
PMID24793884C74 DMFSJQC Discovery agent N.A. Investigative [32]
PMID24793884C77 DMZENGX Discovery agent N.A. Investigative [32]
PHA-767491 DM4H7D5 Discovery agent N.A. Investigative [33]
⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
CDC7-related kinase (CDC7) TTSMTDI CDC7_HUMAN Inhibitor [1]
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [1]
Cyclin-dependent kinase 2 (CDK2) TT7HF4W CDK2_HUMAN Inhibitor [1]
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [1]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [1]
TAO kinase 3 (TAOK3) TTO7L0V TAOK3_HUMAN Inhibitor [1]

References

1 First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293-307.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
4 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
5 Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
6 Clinical pipeline report, company report or official report of BioTheryX.
7 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
8 VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia. Leukemia. 2023 Feb;37(2):326-338.
9 ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
10 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
11 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
12 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
13 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
14 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
15 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
16 Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
17 Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
18 ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
19 Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
22 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
23 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
24 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
25 Company report (Neurim Pharmaceuticals)
26 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
27 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
28 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
29 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
30 Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727-31.
31 Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296-315.
32 Synthesis and structure-activity relationship of trisubstituted thiazoles as Cdc7 kinase inhibitors. Eur J Med Chem. 2014 Jun 10;80:364-82.
33 Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255-64.